ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,181.59
0.02%
Dow Jones
38,858.12
0.02%
US Dollar vs MXN
16.9347
0.29%
Brent Oil
83.085
-0.47%
Bitcoin
62,983.21
-0.29%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Candel Therapeutics Inc (CADL)

  7. Candel Therapeutics Inc (CADL) Noticias

CADL Candel Therapeutics Inc

9.38
0.53 (5.99%)
Última actualización: 13:22:02
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Candel Therapeutics Inc CADL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.53 5.99% 9.38 13:22:02
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
9.00 8.66 9.6299 8.85
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202407:00GLOBECandel Therapeutics Announces Upcoming Presentations at the..
11/4/202408:00GLOBECandel Therapeutics Receives FDA Orphan Drug Designation for..
09/4/202407:00GLOBECandel Therapeutics Presents Preclinical Data at AACR on..
04/4/202407:00GLOBECandel Therapeutics Announces Positive Interim Data from..
28/3/202415:05GLOBECandel Therapeutics Announces Oral Presentation During the..
28/3/202407:05GLOBECandel Therapeutics Reports Fourth Quarter and Full Year..
06/3/202407:00EDGAR2Form 8-K - Current report
05/3/202415:30GLOBECandel Therapeutics Announces an Upcoming Presentation at..
13/2/202408:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202406:45EDGAR2Form 8-K - Current report
13/2/202406:30GLOBECAN-3110 Receives FDA Fast Track Designation for Treatment..
05/2/202407:00GLOBECandel Therapeutics Sets Path to Success: Recent..
19/1/202407:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/1/202415:30EDGAR2Form 8-K - Current report
03/1/202407:30EDGAR2Form 8-K - Current report
12/12/202307:58DJNCandel Therapeutics Shares Soar After FDA Fast Track of..
12/12/202307:30EDGAR2Form 8-K - Current report
12/12/202307:00GLOBECandel Therapeutics Receives FDA Fast Track Designation for..
30/11/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202308:00EDGAR2Form 8-K - Current report
28/11/202308:00GLOBECandel Therapeutics Announces Restructuring to Prioritize..
21/11/202316:00EDGAR2Form 8-K - Current report
09/11/202307:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202307:16EDGAR2Form 8-K - Current report
09/11/202307:00GLOBECandel Therapeutics Reports Third Quarter 2023 Financial..
06/11/202307:53EDGAR2Form 8-K - Current report
06/11/202307:15EDGAR2Form 8-K - Current report
04/11/202307:00GLOBECandel Therapeutics Presents Preclinical Data from its..
03/11/202311:00GLOBECandel Therapeutics Announces Initial Positive Interim Data..
18/10/202310:31EDGAR2Form 8-K - Current report
18/10/202310:00GLOBECandel Therapeutics Announces Nature Publication Showing..
27/9/202308:40GLOBECandel Therapeutics Announces Three Abstracts Accepted for..
26/9/202307:30EDGAR2Form 8-K - Current report
26/9/202307:00GLOBECandel Therapeutics Reports Encouraging Initial Survival..
06/9/202307:00GLOBECandel Therapeutics to Participate in the H.C. Wainwright..
10/8/202307:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202307:15EDGAR2Form 8-K - Current report
10/8/202307:00GLOBECandel Therapeutics Reports Second Quarter 2023 Financial..
02/8/202307:00GLOBECandel Therapeutics to Participate in the Canaccord Genuity..
29/6/202308:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202308:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202308:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202307:31EDGAR2Form 8-K - Current report
13/6/202307:00GLOBECandel Therapeutics Announces It Expects to Report Topline..
08/6/202307:00GLOBECandel Therapeutics Appoints Experienced Manufacturing..

Su Consulta Reciente

NASDAQ
CADL
Candel Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados